Shares in Trellus Health PLC (AIM:TRLS) soared 180% after the company announced a collaboration with Johnson & Johnson (NYSE:JNJ (NYSE:JNJ)) Health Care Systems Inc.
The partnership will pilot Trellus Health’s digital platform, Trellus Elevate, in the US to support patients with moderate to severe inflammatory bowel disease (IBD).
Under the agreement, Trellus will receive an upfront licensing fee and a fixed monthly management fee during the one-year trial.
The platform integrates data analytics with personalised resilience programs, aiming to help patients manage the emotional and physical challenges of chronic conditions, adhere to treatment plans, and take control of their health.
Eligible patients prescribed Johnson & Johnson therapies will gain access to Trellus Elevate as part of the pharmaceutical company’s patient support programmes.
In the first hour of trading the stock was changing hands for 1.68p, up 1.08p.
Read more on Proactive Investors UK
Should you invest $2,000 in ITRM right now?
With ITRM making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed ITRM alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including ITRM, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is ITRM poised for similar growth? Don't miss the opportunity to find out.
Reveal Undervalued Stocks Now